Transgene plots a course through the cancer vaccine graveyard
This article was originally published in Scrip
Executive Summary
French gene and cellular therapy company,Transgene, has developed a triple-pronged strategy that, the company hopes, will help its cancer vaccine, TG4010, steer successfully through clinical trial that are due to start later in 2011. Professor Angus Dalgleish, a key clinical advisor to Transgene, told Scrip at the company’s R&D day at the end of May that the key to avoiding earlier failures with cancer vaccines lay in judicious patient selection, early administration and their use in combination with radio and chemotherapy.